Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs MobilEye Global Inc (MBLY) Price & Performance

Abbott LaboratoriesTrade
MobilEye Global IncTrade

Price performance (Past 24H)

Key statistics

Abbott Laboratories vs MobilEye Global Inc — how do they compare? Abbott Laboratories trades at $109.09 (market cap $187.95B), while MobilEye Global Inc trades at $8.94 (market cap $7.54B). The key difference: Abbott Laboratories is far larger — about 24.9× MobilEye Global Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals.

ABTMBLY
Market Cap
$187.95B$7.54B
Sector
HealthTechnology
52-Week High
$136.62$15.54
52-Week Low
$82.57$6.56
Enterprise Value
$214.96B$6.10B
Dividend Yield
2.32%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.

Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.

MobilEye Global Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About MobilEye Global Inc

Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.

Read more on MBLY